This study is in progress, not accepting new patients
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
Summary
- Eligibility
- for people ages 18-99 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Robin Kate Kelley
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- MedImmune LLC
- ID
- NCT02519348
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated